Table S2: Known MS biomarkers with supporting references.

Biomarker	Tissue	References
NfL	CSF, Plasma	[1-5]
C1QA	CSF	[6, 7]
CD27	CSF	[8, 9]
CHI3L1	CSF, Plasma	[5, 10-12]
CCL2	CSF	[12, 13]
CCL22	CSF	[5, 14]
CXCL1	CSF	[5, 14]
CXCL10	CSF, Plasma	[5, 14, 15]
CXCL13	CSF	[5, 12]
MMP9	CSF	[5]
OPN	CSF	[16]
CXCL8	CSF	[5]
GFAP	CSF, Plasma	[17]

1. Disanto, G., et al., Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Annals of neurology, 2017. 81(6): p. 857-870.
2. van den Bosch, A., et al., Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage. Neurology-Neuroimmunology Neuroinflammation, 2022. 9(3).
3. Harris, S., et al., Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials. European Journal of Neurology, 2021. 28(11): p. 3722-3730.
4. Håkansson, I., et al., Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. Journal of neuroinflammation, 2018. 15(1): p. 1-10.
5. Håkansson, I., et al., Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis. European journal of neurology, 2017. 24(5): p. 703-712.
6. Håkansson, I., et al., Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis. Journal of Neuroimmunology, 2020. 340: p. 577147.
7. Lindblom, R.P., et al., Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function. Clinical Immunology, 2016. 166: p. 89-95.
8. Mescheriakova, J.Y., et al., Soluble CD27 levels in cerebrospinal fluid as a prognostic biomarker in clinically isolated syndrome. JAMA neurology, 2017. 74(3): p. 286-292.
9. Magnusson, R., et al., RNA-sequencing and mass-spectrometry proteomic time-series analysis of T-cell differentiation identified multiple splice variants models that predicted validated protein biomarkers in inflammatory diseases. Frontiers in molecular biosciences, 2022: p. 892.
10. De Fino, C., et al., The predictive value of CSF multiple assay in multiple sclerosis: a single center experience. Multiple Sclerosis and Related Disorders, 2019. 35: p. 176-181.
11. Hinsinger, G., et al., Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis Journal, 2015. 21(10): p. 1251-1261.

12. Lucchini, M., et al., CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis. Molecular Neurobiology, 2022: p. 1-15.
13. Mahad, D., S. Howell, and M. Woodroofe, Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 2002. 72(4): p. 498-502.
14. Burman, J., et al., The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. Journal of neuroimmunology, 2014. 277(1-2): p. 153-159.
15. Sørensen, T., et al., Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. European journal of neurology, 2001. 8(6): p. 665-672.
16. Huang, J., et al., Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proceedings of the National Academy of Sciences, 2020. 117(23): p. 12952-12960.
17. Kuhle, J., et al., Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Are Prognostic of Disability Worsening: A Biosignature That Helps Differentiating Active From Non-active SPMS (2580). 2021, AAN Enterprises.